FDA Alignment Is a Starting Point, Not a Rare Disease Strategy for the European Market

Posted
[Sponsored] For US biotech companies developing rare disease therapies, decisions about clinical evidence, patient populations and regulatory advice can have consequences in Europe long before a marketing application is submitted. The post FDA Alignment Is a Starting Point, Not a Rare Disease Strategy for the European Market appeared first on MedCity News.

Continue reading at MedCity News »

BioPharma, Daily, Policy, Sponsored Post, biopharma nl, clinical trial design, drug development, FDA, orphan drug, Presented by VCLS, rare disease, Sponsored Content, VCLS